智通财经APP讯，金斯瑞生物科技(01548)发布公告，于2024年12月20日，根据日期为2021年8月24日的可转换债券文书(经日期为2024年12月18日的修订协议修订)，公司行使其权利，将7000万美元的可转换债券转换为1.06亿股Probio Cayman普通股(转换股份)，转换价为每股转换股份0.66美元。因此，Probio Cayman将向公司配发及发行1.06亿股转换股份。
紧随转换后，不考虑未来配发和发行员工持股计划股份并假设Probio A类认股权证未获行使，Probio Cayman由公司直接和间接拥有约71.72%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.